Literature DB >> 12424696

Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease.

Steven Jacobson1.   

Abstract

This review focuses on current approaches to understanding the immunopathogenesis of human T cell lymphotropic virus (HTLV) type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) based on newly developed molecular and immunologic techniques that have been adapted to studies of HTLV-I proviral load, HTLV-I mRNA, and HTLV-I tax-specific CD8 T cells. These methods enable researchers to study previously inaccessible aspects of this disease and allow a more detailed analysis of virus/host immune responses as they relate to disease specificity in this disorder. The role of HTLV-I-specific CD8 T cell immune responses is highlighted. The elucidation of the immunopathology of HAM/TSP will enhance our understanding of other HTLV-I-associated disorders plus other neurologic, hematologic, and inflammatory diseases for which viral etiologies have been suggested.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424696     DOI: 10.1086/344269

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Human T-lymphotropic virus type I or II (HTLV-I/II) associated with recurrent longitudinally extensive transverse myelitis (LETM): two case reports.

Authors:  Silvia R Delgado; William A Sheremata; Andrew D Brown; Micheline McCarthy
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-I-associated neurologic disease.

Authors:  Unsong Oh; Matthew J McCormick; Dibyadeep Datta; Richard V Turner; Kathryn Bobb; Dileep D Monie; D Robert Sliskovic; Yuetsu Tanaka; Jie Zhang; Jeffrey Meshulam; Steven Jacobson
Journal:  Blood       Date:  2011-01-06       Impact factor: 22.113

3.  HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death.

Authors:  David Sibon; Anne-Sophie Gabet; Marc Zandecki; Christiane Pinatel; Julien Thête; Marie-Hélène Delfau-Larue; Samira Rabaaoui; Antoine Gessain; Olivier Gout; Steven Jacobson; Franck Mortreux; Eric Wattel
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

4.  Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals.

Authors:  T Luna; S B Santos; M Nascimento; M A F Porto; A L Muniz; E M Carvalho; A R Jesus
Journal:  Braz J Med Biol Res       Date:  2011-10-22       Impact factor: 2.590

5.  Role of neuronal interferon-gamma in the development of myelopathy in rats infected with human T-cell leukemia virus type 1.

Authors:  Yukiko Miyatake; Hitoshi Ikeda; Akihiro Ishizu; Tomohisa Baba; Toru Ichihashi; Akira Suzuki; Utano Tomaru; Masanori Kasahara; Takashi Yoshiki
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

6.  Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state.

Authors:  J B Guerreiro; S B Santos; D J Morgan; A F Porto; A L Muniz; J L Ho; A L Teixeira; M M Teixeira; E M Carvalho
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 7.  Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control.

Authors:  Charles R M Bangham
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 8.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Marco A Lima; Ramza C Harab; Doris Schor; Maria J Andrada-Serpa; Abelardo Q C Araújo
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

10.  Lower numbers of circulating Natural Killer T (NK T) cells in individuals with human T lymphotropic virus type 1 (HTLV-1) associated neurological disease.

Authors:  L C Ndhlovu; J E Snyder-Cappione; K I Carvalho; F E Leal; C P Loo; F R Bruno; A R Jha; D Devita; A M Hasenkrug; H M R Barbosa; A C Segurado; D F Nixon; E L Murphy; E G Kallas
Journal:  Clin Exp Immunol       Date:  2009-09-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.